Major Depressive Episode Clinical Trial
Official title:
N-3 Polyunsaturated Fatty Acids in the Prevention and Treatment for IFN-induced Depression
The first part is a double-blind placebo-controlled trial to identify the effects of omega-3 polyunsaturated fatty acids (PUFAs) in prevention of IFN-induced depression. The second part is a double-blind trial to identify the antidepressant effects of omega-3 PUFAs in patients with IFN-induced depression.
We have done a preliminary analysis in 63 HCV patients receiving IFN-α therapy enrolled in
our current NSC project (NSC95-2320-B-039-037-MY3) and found that patients who later
developed IFN-α-induced depression (case group, 21/63) had lower PUFA levels before starting
IFN-α therapy than control group (p=0.024). In addition, there was a trend for a negative
correlation (r=-0.224; p=0.078) between baseline DHA levels and the highest scores of BDI
during IFN therapy in the whole group. These findings indicate that n-3 PUFAs might play a
protective factor.
This 3-year proposal is divided into 2 clinical studies. In study 1, we aim to test the
prophylactic effect of n-3 PUFAs (EPA: 3.5 g/d and DHA: 1.75 g/d versus placebo: high oleic
oil) for IFN-α-induced sickness behaviour and depressive symptoms, in a two-week,
double-blind, placebo-controlled trial of 152 patients with HCV starting IFN-α therapy. In
study 2, we will test the antidepressant effect of n-3 PUFAs (EPA: 3.5 g/d and DHA: 1.75 g/d
versus placebo: high oleic oil) on IFN-α-induced depression during IFN-α therapy, in an
eight-week, double-blind, placebo-controlled trial in 80 HCV patients who have already
developed depression.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03256162 -
Ketamine as an Adjunctive Therapy for Major Depression
|
Phase 1 | |
Completed |
NCT01944293 -
Ketamine for Suicidality in Bipolar Depression
|
Phase 1/Phase 2 | |
Recruiting |
NCT01441505 -
A Study of Ketamine as an Antidepressant
|
Phase 2 | |
Active, not recruiting |
NCT03487926 -
Microglial Activation in Inflammatory Bowel Disease
|
||
Recruiting |
NCT04939649 -
Ketamine as an Adjunctive Therapy for Major Depression (2)
|
Phase 3 | |
Recruiting |
NCT05028738 -
Patient-oriented Randomized Pragmatic Feasibility Trial With rTMS in Depression and Anxiety
|
N/A | |
Recruiting |
NCT03646058 -
Add-on Buprenorphine at Analgesic Doses for the Treatment of Severe Suicidal Ideas During a Major Depressive Episode
|
Phase 3 | |
Not yet recruiting |
NCT06117397 -
A Text Messaging Intervention to Reduce Perinatal Depression Risk
|
N/A | |
Completed |
NCT03735576 -
Cognitive Behavioural Therapy for the Treatment of Late Life Depression
|
N/A | |
Recruiting |
NCT04999553 -
Left vs. Right Non-Inferiority Trial
|
N/A | |
Completed |
NCT03716869 -
Universal vs. Targeted School Screening for Adolescent Major Depressive Disorder
|
N/A | |
Recruiting |
NCT02824081 -
Neuroinflammation, Serotonin, Impulsivity and Suicide
|
N/A | |
Terminated |
NCT01099592 -
Antidepressants to Promote Recovery of Cardiac Patients Suffering From Depression
|
Phase 4 | |
Completed |
NCT03752853 -
Stress Systems and Psychotherapy in Depression
|
N/A | |
Recruiting |
NCT04480918 -
University of Iowa Interventional Psychiatry Service Patient Registry
|
||
Recruiting |
NCT04130958 -
Circuit-Based Approach to Suicide: Biomarkers, Predictors, and Novel Therapeutics
|
N/A | |
Completed |
NCT03190772 -
The Role of Expectations in the Pharmacological Treatment of Depression - An Experimental Investigation
|
N/A | |
Recruiting |
NCT04832750 -
Depression-Reduction by Accelerated Personalized NeuroModulation and Its Effects on Sleep
|
||
Terminated |
NCT02839798 -
NeoSync TMS Treatment for Bipolar I Depression
|
Phase 2 | |
Completed |
NCT00852592 -
Light Therapy for Bipolar Disorder. Efficacy of Light Therapy for Bipolar Depression: A Randomized Controlled Trial
|
Phase 3 |